

DAFTAR PUSTAKA

- Adam, M.A., Thomas, S., Hyslop, T., Scheri, R.P., Roman, S.A. & Sosa, J.A., 2016. Exploring the relationship between patient age and cancer-specific survival in papillary thyroid cancer: rethinking current staging systems. *Journal of Clinical Oncology*, 34(36), 4415.
- Ahn D, Lee GJ & Sohn JH. 2020. Recurrence following hemithyroidectomy in patients with low- and intermediate-risk papillary thyroid carcinoma. *Br J Surg*, 107(6):687-694. doi: 10.1002/bjs.11430. Epub 2020 Feb 5. PMID: 32026467.
- Amit, M., Boonsripitayanon, M., Goepfert, R. P., Tam, S., Busaidy, N. L., Cabanillas, M. E. & Zafereo, M. E. 2018. *Extrathyroidal Extension: Does Strap Muscle Invasion Alone Influence Recurrence and Survival in Patients with Differentiated Thyroid Cancer? Annals of Surgical Oncology*. doi:10.1245/s10434-018-6563-x
- Burns, W.R. and Zeiger, M.A., 2010. Differentiated thyroid cancer. In *Seminars in oncology*. WB Saunders, 37(6), 557-566.
- Craig, W.L., Smart, L., Fielding, S., Ramsay, C. & Krukowski, Z.H., 2018. Long term outcomes of simple clinical risk stratification in management of differentiated thyroid cancer. *The Surgeon*, 16(5), 283-291.
- Cushing, S. L., Palme, C. E., Audet, N., Eski, S., Walfish, P. G., & Freeman, J. L. 2004. *Prognostic Factors in Well-Differentiated Thyroid Carcinoma. The Laryngoscope*, 114(12), 2110–2115. doi:10.1097/01.mlg.0000149442.223
- Dean, D.S. & Hay, I.D., 2000. Prognostic indicators in differentiated thyroid carcinoma. *Cancer control*, 7(3), 229-239.

- Dionigi, G., Fama', F., Pignata, S.A., Pino, A., Pontin, A., Caruso, E., Fu, Y., Li, S., Mazzeo, C., Sun, H. & Baldari, S., 2020. Usefulness of PET-CT scan in recurrent thyroid cancer. *World Journal of Otorhinolaryngology-Head and Neck Surgery*, 6(03), 182-187.
- Drozd, V., Saenko, V., Branovan, D.I., Brown, K., Yamashita, S. & Reiners, C., 2021. A search for causes of rising incidence of differentiated thyroid cancer in children and adolescents after Chernobyl and Fukushima: Comparison of the clinical features and their relevance for treatment and prognosis. *International Journal of Environmental Research and Public Health*, 18(7), 3444.
- Filetti, S., Durante, C., Hartl, D., Leboulleux, S., Locati, L. D., Newbold, K., Papotti, M. G., & Berruti, A. 2019. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*, 30(12), 1856–1883. <https://doi.org/10.1093/annonc/mdz400>
- Furlan, J.C., Bedard, Y.C. and Rosen, I.B., 2004. Clinicopathologic significance of histologic vascular invasion in papillary and follicular thyroid carcinomas. *Journal of the American College of Surgeons*, 198(3), pp.341-348.
- Furuya-Kanamori, L., Bell, K.J., Clark, J. & Glasziou, P., 2016. Prevalence of differentiated thyroid cancer in autopsy studies over six decades: a meta-analysis. *Journal of Clinical Oncology*.
- Furuya-Kanamori, L., Sedrakyan, A., Onitilo, A.A., Bagheri, N., Glasziou, P. & Doi, S.A., 2018. Differentiated thyroid cancer: millions spent with no tangible gain?. *Endocrine-Related Cancer*, 25(1), 51-57.

Glikson, E., Alon, E., Bedrin, L. & Talmi, Y.P., 2017. Prognostic Factors in Differentiated Thyroid Cancer Revisited. *The Israel Medical Association journal: IMAJ*, 19(2), 114-118.

Grønlund MP, Jensen JS, Hahn CH, Grønhøj C. & Buchwald CV. 2021. Risk Factors for Recurrence of Follicular Thyroid Cancer: A Systematic Review. *Thyroid*. 2021 Oct;31(10):1523-1530. doi: 10.1089/thy.2020.0921. PMID: 34102860.

Gulcelik, M. A., Gulcelik, N. E., Kuru, B., Camlibel, M., & Alagol, H. 2007. *Prognostic factors determining survival in differentiated thyroid cancer. Journal of Surgical Oncology*, 96(7), 598–604. doi:10.1002/jso.20845

Guo, K. & Wang, Z., 2014. Risk factors influencing the recurrence of papillary thyroid carcinoma: a systematic review and meta-analysis. *International journal of clinical and experimental pathology*, 7(9), 5393.

Haddad, R. I., Nasr, C., Bischoff, L., Busaidy, N. L., Byrd, D., Callender, G., Dickson, P., Duh, Q. Y., Ehya, H., Goldner, W., Haymart, M., Hoh, C., Hunt, J. P., Iagaru, A., Kandeel, F., Kopp, P., Lamonica, D. M., McIver, B., Raeburn, C. D. & Gurski, L. A. 2018. NCCN Guidelines Insights: Thyroid Carcinoma. *JNCCN Journal of the National Comprehensive Cancer Network*, 16(12), 1429–1440. <https://doi.org/10.6004/jnccn.2018.0089>

Hartl, D.M., Guerlain, J., Breuskin, I., Hadoux, J., Baudin, E., Al Ghuzlan, A., Terroir-Cassou-Mounat, M., Lamartina, L. & Leboulleux, S., 2020. Thyroid lobectomy for low to intermediate risk differentiated thyroid cancer. *Cancers*, 12(11), 3282.

- Hodé, A. , Aziz, S. , Dédjan, A. , Chadli, A. & Farouqi, A. 2020. Characteristics of Persistent or Recurrent Differentiated Thyroid Cancer. *Open Journal of Endocrine and Metabolic Diseases*, 10, 1-5. doi: [10.4236/ojemd.2020.101001](https://doi.org/10.4236/ojemd.2020.101001).
- Hollenbeak CS, Boltz MM, Schaefer EW, Saunders BD. & Goldenberg D. 2013. Recurrence of differentiated thyroid cancer in the elderly. *Eur J Endocrinol*, 168(4), 549-56. doi: [10.1530/EJE-12-0848](https://doi.org/10.1530/EJE-12-0848). PMID: 23337385.
- Jukić T, Blažeković I, Franceschi M, Ovčariček PP, Butković MB, Dabelić N, Granić R, Punda M, Sonicki Z, Vagić D, Fröbe A. & Kusić Z. 2022. Long-Term Outcome of Differentiated Thyroid Cancer Patients-Fifty Years of Croatian Thyroid Disease Referral Centre Experience. *Diagnostics (Basel)*, 12(4), 866. doi: [10.3390/diagnostics12040866](https://doi.org/10.3390/diagnostics12040866). PMID: 35453913; PMCID: PMC9025554.
- Jukkola, A., Bloigu, R., Ebeling, T., Salmela, P. & Blanco, G., 2004. Prognostic factors in differentiated thyroid carcinomas and their implications for current staging classifications. *Endocrine-related cancer*, 11(3), 571-579.
- Kaliszewski, K., Diakowska, D., Nowak, Ł., Wojtczak, B. & Rudnicki, J., 2020. The age threshold of the 8th edition AJCC classification is useful for indicating patients with aggressive papillary thyroid cancer in clinical practice. *BMC cancer*, 20(1), 1-11.
- Lang, B.H.H., Lo, C.Y., Chan, W.F., Lam, K.Y. & Wan, K.Y., 2007. Staging systems for papillary thyroid carcinoma: a review and comparison. *Annals of surgery*, 245(3), 366.

- Lang, B.H.H., Lo, C.Y., Chan, W.F., Lam, K.Y. & Wan, K.Y., 2007. Staging systems for follicular thyroid carcinoma: application to 171 consecutive patients treated in a tertiary referral centre. *Endocrine-related cancer*, 14(1), 29-42.
- Lang, B.H.H., Ng, S.H., Lau, L.L., Cowling, B.J., Wong, K.P. & Wan, K.Y., 2013. A systematic review and meta-analysis of prophylactic central neck dissection on short-term locoregional recurrence in papillary thyroid carcinoma after total thyroidectomy. *Thyroid*, 23(9), 1087-1098.
- Lee, K., Anastasopoulou, C., Chandran, C. & Cassaro, S., 2021. Thyroid Cancer. *StatPearls [Internet]*.
- Lei, S., Ding, Z., Ge, J., & Zhao, D., 2015. Association between prognostic factors and clinical outcome of well-differentiated thyroid carcinoma: A retrospective 10-year follow-up study. *Oncology letters*, 10(3), 1749-1754
- Limaïem, F., Rehman, A. & Mazzoni, T., 2019. Papillary thyroid carcinoma.
- Ma, B., Xu, W., Wei, W., Wen, D., Lu, Z., Yang, S., Chen, T., Wang, Y., Wang, Y. & Ji, Q., 2018. Clinicopathological and survival outcomes of well-differentiated thyroid carcinoma undergoing dedifferentiation: a retrospective study from FUSCC. *International journal of endocrinology*, 2018.
- Makazlieva, T., Vaskova, O., Stojanoski, S., Nevena, M., Miladinova, D. & Stefanovska, V.V., 2019. Prognostic factors in thyroid carcinomas: a 17-year outcome study. *Archives of endocrinology and metabolism*, 64, 30-37.
- Mao J, Zhang Q, Zhang H, Zheng K, Wang R. & Wang G. 2020. Risk Factors for Lymph Node Metastasis in Papillary Thyroid Carcinoma: A Systematic Review and Meta-

Analysis. *Front Endocrinol (Lausanne)*. 11(265). doi: 10.3389/fendo.2020.00265.

PMID: 32477264; PMCID: PMC7242632.

Metere, A., Aceti, V., & Giacomelli, L. 2019. The surgical management of locally advanced well-differentiated thyroid carcinoma: changes over the years according to the AJCC 8th edition Cancer Staging Manual. *Thyroid Research*, 1–7.

Moleti M, Sturniolo G, Di Mauro M, Russo M. & Vermiglio F. 2017. Female Reproductive Factors and Differentiated Thyroid Cancer. *Front Endocrinol (Lausanne)*, 8:111. doi: 10.3389/fendo.2017.00111. PMID: 28588554; PMCID: PMC5440523.

Olson, E., Wintheiser, G., Wolfe, K.M., Droessler, J. & Silberstein, P.T., 2019. Epidemiology of thyroid cancer: a review of the National Cancer Database, 2000-2013. *Cureus*, 11(2).

Palme CE, Waseem Z, Raza SN, Eski S, Walfish P. & Freeman JL. 2004. Management and outcome of recurrent well-differentiated thyroid carcinoma. *Arch Otolaryngol Head Neck Surg*, 130(7), 819-24. doi: 10.1001/archotol.130.7.819. PMID: 15262757.

Pangribowo, S., 2019. Beban Kanker di Indonesia. InfoDATIN, Pusat Data dan Informasi Kementerian Kesehatan RI.

Sanabria, A., Kowalski, L.P., Shah, J.P., Nixon, I.J., Angelos, P., Williams, M.D., Rinaldo, A. & Ferlito, A., 2018. Growing incidence of thyroid carcinoma in recent years: factors underlying overdiagnosis. *Head & neck*, 40(4), 855-866.

Shaha, A. 2006. *Treatment of thyroid cancer based on risk groups. Journal of Surgical Oncology*, 94(8), 683–691. doi:10.1002/jso.20697

Suh, Y. J., Kwon, H., Kim, S., Choi, J. Y., Lee, K. E., Park, Y. J. & Youn, Y.-K.

2015. *Factors Affecting the Locoregional Recurrence of Conventional Papillary Thyroid Carcinoma After Surgery: A Retrospective Analysis of 3381 Patients. Annals of Surgical Oncology*, 22(11), 3543–3549. doi:10.1245/s10434-015-4448-9

Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A. & Bray, F., 2021. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: a cancer journal for clinicians*, 71(3), 209-249.

Stewart, L.A. & Kuo, J.H., 2021. Advancements in the treatment of differentiated thyroid cancer. *Therapeutic Advances in Endocrinology and Metabolism*, 12, p.20420188211000251.

Teo, K.W., Yuan, N.K., Tan, W.B. & Parameswaran, R., 2017. Comparison of prognostic scoring systems in follicular thyroid cancer. *The Annals of The Royal College of Surgeons of England*, 99(6), 479-484.

Verburg, F.A., Mader, U., Kruitwagen, C.L., Luster, M., & Reiners, C., 2010. A comparison of prognostic classification systems for differentiated thyroid carcinoma. *Clinical endocrinology*, 72(6), 830-838

Wada, N., Hasegawa, S., Masudo, Y., Hirakawa, S., Matsuzu, K., Suganuma, N., Nakayama, H., Rino, Y., & Imada, T., 2007. Clinical outcome by AMES risk definition in Japanese differentiated thyroid carcinoma patients. *Asian Journal of Surgery*, 30 (2), 102-107

Woo J, Kim H. & Kwon H. 2021. Impact of Multifocality on the Recurrence of Papillary Thyroid Carcinoma. *J Clin Med*, 10(21), 5144. doi: 10.3390/jcm10215144. PMID: 34768664; PMCID: PMC8584384.

Ye, B., Shi, J., Shen, C., Wang, L., Hu, H., Ma, Y., Wang, Q., Lu, J., Yu, G. & Xiang, M., 2017. Comparison of differentiated thyroid carcinoma recurrence and its clinical features in children of different ages. *Oncotarget*, 8(29), 48051.



**SCORING AGES DAN AMES PADA KANKER TIROID TERDIFERENSIASI, ASOSIASI DENGAN
KEKAMBUHAN LOKOREGIONAL**

FABGUTATWA DIATMIKA, dr. Herjuna Hardiyanto, Sp.B(K) Onk; dr. Sumadi Lukman Anwar, M.Sc., Ph.D., Sp.B(K) Onk

Universitas Gadjah Mada, 2022. Diunduh dari <http://etd.repository.ugm.ac.id/>

UNIVERSITAS
GADJAH MADA



ETHICS COMMITTEE APPROVAL

Ref. No. : KE/FK/1255/EC/2022

Title of the Research Protocol : Scoring Ages dan Ames pada • Kanker Thyroid
Terdiferensiasi, Asosiasi dengan Kekambuhan Lokoregional

Document(s) Approved and version : Study Protocol version 01 2022

Principle Investigator : Ida Bagus Gde Tatwa Diatmika

Participating Investigator(s) : 1. dr. Herjuna Hardiyanto, Sp.B(K) Onk.
2. dr. Sumadi Lukman Anwar, M.Sc., Ph.D., Sp.B(K) Onk.

Date of Approval : **03 OCT 2022**
(Valid for one year beginning from the date of approval)

Institution(s)/place(s) of research : RSUP Dr. Sardjito Yogyakarta

The Medical and Health Research Ethics Committee (MHREC) states that the document above meets the ethical principle outlined in the International and National Guidelines on ethical standards and procedures for researches with human beings.

The Medical and Health Research Ethics Committee (MHREC) has the right to monitor the research activities at any time.

The investigator(s) is/are obliged to submit:

- ☒ Progress report as a continuing review (state its due time)
- ☒ Report of any serious adverse events (SAE)
- ☒ Final report upon the completion of the study

Dr. dr. Eti Nurwening Sholikhah, M.Kes., M.Med.Ed.
Panel's vice chairperson

dr. Rizka Humardewayanti A., Sp.PD-KPTI.
Panel's secretary

P.S: This letter uses signature scan of the panel's chairperson and Secretary of the Ethics Committee. The hardcopy official letter with authority's signature will be issued when it is possible and are kept as an archive of the Ethics Committee

Validation number :
633a558e817a3
(<http://komisietk.fk.ugm.ac.id/validasi>)

